| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 314 | 613 | 729 | 856 | 980 | 815 | 931 | 897 | 802 | 692 | 791 | 805 | 1,266 | 478 | 530 | 862 | 662 | 696 | 842 | 760 | 641 | 839 | 834 | 845 | 922 | 702 | 744 | 805 | 952 | 954 | 954 | 933 | 1,014 | 939 | 1,035 | 1,075 | 1,030 | 1,100 | 1,195 | 1,160 | 1,206 |
| Expenses | 274 | 564 | 628 | 728 | 855 | 676 | 730 | 602 | 577 | 595 | 688 | 627 | 604 | 448 | 496 | 516 | 572 | 612 | 610 | 574 | 772 | 648 | 662 | 712 | 773 | 850 | 818 | 833 | 944 | 1,002 | 844 | 892 | 879 | 802 | 1,054 | 886 | 888 | 886 | 987 | 946 | 1,000 |
| EBITDA | 40 | 50 | 101 | 128 | 125 | 140 | 201 | 295 | 225 | 97 | 103 | 178 | 663 | 30 | 34 | 346 | 90 | 84 | 232 | 187 | -131 | 191 | 173 | 133 | 149 | -148 | -75 | -28 | 8 | -49 | 110 | 41 | 135 | 136 | -18 | 189 | 142 | 214 | 209 | 215 | 206 |
| Operating Profit % | 11 % | 3 % | 7 % | 13 % | 8 % | 14 % | 16 % | 17 % | 15 % | 10 % | 11 % | 16 % | 10 % | 5 % | 5 % | 10 % | 7 % | 11 % | 15 % | 22 % | -25 % | 17 % | 17 % | 14 % | 15 % | -23 % | -13 % | -5 % | -9 % | -7 % | 6 % | -3 % | 11 % | 14 % | -5 % | 12 % | 15 % | 19 % | 15 % | 18 % | 16 % |
| Depreciation | 20 | 32 | 36 | 40 | 39 | 42 | 44 | 31 | 38 | 35 | 37 | 38 | 44 | 29 | 31 | 28 | 30 | 43 | 42 | 44 | 45 | 49 | 53 | 53 | 52 | 55 | 57 | 61 | 61 | 60 | 62 | 60 | 61 | 60 | 60 | 49 | 48 | 49 | 49 | 48 | 49 |
| Interest | 15 | 28 | 34 | 54 | 62 | 56 | 58 | 44 | 48 | 52 | 49 | 50 | 46 | 17 | 17 | 22 | 23 | 35 | 40 | 40 | 40 | 37 | 37 | 35 | 42 | 42 | 44 | 42 | 50 | 55 | 68 | 58 | 81 | 76 | 79 | 70 | 71 | 80 | 74 | 52 | 50 |
| Profit Before Tax | 33 | 19 | 69 | 68 | 24 | 41 | 98 | 220 | 140 | 10 | 17 | 90 | 573 | -16 | -14 | 296 | 37 | 6 | 149 | 104 | -217 | 105 | 83 | 46 | 55 | -244 | -175 | -131 | -103 | -163 | -20 | -78 | -7 | 0 | -157 | 70 | 23 | 85 | 86 | 114 | 106 |
| Tax | 22 | 9 | 34 | 10 | 20 | 9 | 13 | 24 | 8 | 4 | 5 | 2 | -5 | -14 | -6 | -0 | -8 | 3 | 7 | 11 | -11 | 3 | 6 | 11 | 12 | -36 | -7 | -5 | -132 | -28 | -38 | 4 | 7 | 10 | -7 | 16 | 13 | 17 | 14 | 24 | 21 |
| Net Profit | 11 | 10 | 35 | 58 | 4 | 33 | 85 | 196 | 132 | 6 | 12 | 88 | 578 | -3 | -9 | 296 | 45 | 3 | 142 | 92 | -207 | 102 | 77 | 35 | 44 | -209 | -168 | -127 | 29 | -135 | 19 | -82 | -14 | -9 | -150 | 54 | 10 | 68 | 72 | 90 | 86 |
| EPS in ₹ | 1.91 | 1.34 | 4.44 | 6.59 | 1.74 | 2.91 | 8.29 | 20.96 | 12.57 | 0.06 | 0.96 | 9.55 | 63.56 | -0.48 | -1.34 | 32.77 | 5.31 | 0.41 | 15.94 | 10.48 | -22.77 | 11.56 | 9.03 | 4.22 | 5.14 | -22.88 | -18.12 | -13.55 | 3.25 | -15.13 | 2.54 | -8.86 | -1.06 | -0.79 | -14.54 | 5.43 | 1.98 | 7.64 | 7.81 | 9.56 | 8.92 |
Strides Pharma Science
782.30
-7.50
(-0.95%)
Market Cap
7,209.90 Cr
EPS
-7.76
PE Ratio
20.49
Dividend Yield
0.51 %
Industry
Healthcare52 Week High
1,675.00
52 Week Low
390.15
PB Ratio
2.82
Debt to Equity
1.28
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.20 | #1 4,02,896.30 | 35.14 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 43.89 | |
6,544.50 | 1,73,735.90 | 79.38 | 8,184.00 | 0.89 | 1,600 | 23.05 | 57.72 | |
1,504.20 | 1,21,481.40 | 23.04 | 26,520.70 | 14.17 | 4,155 | 30.28 | 55.17 | |
1,320.90 | 1,10,223.20 | #1 19.49 | 28,905.40 | 12.36 | 5,578 | 21.14 | 80.62 | |
3,154.30 | 1,06,755.80 | 55.37 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.00 | |
2,352.40 | 97,055.00 | 48.88 | 10,615.60 | 19.57 | 1,942 | -10.91 | 37.92 | |
960.15 | 96,613.60 | 20.69 | 19,831.50 | 13.82 | 3,831 | -0.19 | 71.38 | |
1,999.60 | 91,289.90 | 27.82 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 50.41 | |
1,161.10 | 67,436.90 | 19.51 | 29,559.20 | 17.55 | 3,169 | -0.50 | 47.11 | |
31,630.00 | 67,211.50 | 47.70 | 6,097.20 | 10.80 | 1,201 | 27.83 | 63.13 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
8.26 %
Net Income Growth
-35.69 %
Cash Flow Change
1,478.63 %
ROE
-32.55 %
ROCE
-1,066.67 %
EBITDA Margin (Avg.)
39.00 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 2,475 | 7,659 | 8,105 | 6,708 | 7,980 | 6,152 | 7,015 | 6,976 | 6,638 | 5,840 |
| Fixed Assets | 701 | 2,499 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 |
| Current Assets | 1,429 | 3,595 | 3,792 | 2,484 | 3,049 | 2,372 | 2,817 | 3,362 | 3,243 | 2,969 |
| Capital Work in Progress | 171 | 1,200 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 |
| Investments | 561 | 1,260 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 |
| Other Assets | 1,041 | 2,700 | 2,821 | 2,524 | 3,177 | 3,091 | 3,651 | 3,798 | 3,687 | 3,510 |
| Total Liabilities | 2,475 | 7,659 | 8,105 | 6,708 | 7,980 | 6,152 | 7,015 | 6,976 | 6,638 | 5,840 |
| Current Liabilities | 1,020 | 1,940 | 3,104 | 1,899 | 2,662 | 2,545 | 2,738 | 3,412 | 2,990 | 2,879 |
| Non Current Liabilities | 291 | 2,813 | 2,119 | 2,191 | 2,516 | 1,012 | 1,463 | 1,181 | 1,475 | 889 |
| Total Equity | 1,164 | 2,906 | 2,882 | 2,618 | 2,802 | 2,595 | 2,814 | 2,383 | 2,173 | 2,072 |
| Reserve & Surplus | 1,085 | 2,774 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,105 | 2,034 |
| Share Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -143 |
| Investing Activities | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 |
| Operating Activities | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 |
| Financing Activities | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 29.67 % | 29.62 % | 29.60 % | 29.60 % | 30.60 % | 30.37 % | 31.07 % | 30.89 % | 28.27 % | 28.07 % | 27.78 % | 27.39 % | 25.88 % | 25.86 % | 25.84 % | 26.82 % | 28.30 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.05 % | 0.05 % | 0.05 % | 0.05 % | 0.00 % | 0.00 % | 24.57 % | 26.71 % | 30.08 % | 28.48 % | 28.32 % |
| DIIs | 14.82 % | 13.23 % | 14.22 % | 14.85 % | 12.40 % | 9.82 % | 13.59 % | 18.84 % | 18.29 % | 20.00 % | 18.22 % | 17.56 % | 18.04 % | 18.56 % | 18.24 % | 16.92 % | 13.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 14.01 % | 16.64 % | 17.89 % | 20.42 % | 21.82 % | 22.29 % | 22.40 % | 22.43 % | 25.51 % | 24.93 % | 23.39 % | 22.65 % | 21.19 % | 20.87 % | 18.57 % | 20.86 % | 21.52 % |
| Others | 41.49 % | 40.51 % | 38.29 % | 35.12 % | 35.19 % | 37.51 % | 32.88 % | 27.77 % | 27.86 % | 26.93 % | 30.60 % | 32.39 % | 10.32 % | 8.00 % | 7.26 % | 6.90 % | 8.14 % |
| No of Share Holders | 74,074 | 96,976 | 1,06,927 | 1,25,553 | 1,33,190 | 1,34,718 | 1,30,682 | 1,23,964 | 1,20,916 | 1,12,775 | 1,01,638 | 91,182 | 84,695 | 91,917 | 96,009 | 1,14,236 | 95,125 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 4.5 | 0.00 | 0.00 | 14 | 0.00 | 0.00 | 0.00 | 2.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.69 | 0.00 | 0.00 | 1.66 | 0.00 | 0.00 | 0.00 | 0.37 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 May 2025 |  Quarterly Result Announcement | NA | 22 May 2025 | 663.35 | 694.95 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 628.20 | 608.70 |
| 24 Oct 2024 | Quarterly Result Announcement | NA | 24 Oct 2024 | 720.09 | 683.70 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 597.53 | 611.51 |
| 10 Sept 2024 |  Extraordinary General Meeting | NA | 10 Sept 2024 | 488.59 | 572.84 |
| 09 Sept 2024 |  Dividend | ₹ 2.50 /share | 09 Sept 2024 | 370.78 | 595.84 |
| 28 Aug 2023 | Annual General Meeting | NA | 28 Aug 2023 | 193.07 | 192.90 |
| 04 Aug 2023 | Dividend | ₹ 1.50 /share | 04 Aug 2023 | 165.46 | 194.41 |
| 06 Aug 2021 | Dividend | ₹ 2.50 /share | 05 Aug 2021 | 356.19 | 342.54 |
| 18 Jul 2018 |  Change Of Name | NA | 18 Jul 2018 | 157.75 | 157.75 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
May 27, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Intimation Pursuant To Regulation 31A Of The Sebl (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Promoter ReclassificationMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
May 22, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On May 22 2025May 22, 2025
May 22, 2025Update On Promoters Reclassification RequestMay 22, 2025
May 22, 2025Appointment Of Secretarial AuditorMay 22, 2025
May 22, 2025Corporate Action-Board approves DividendMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2025
May 22, 2025Outcome Of Board Meeting Of The Company Held On May 22 2025May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementMay 15, 2025
May 15, 2025Intimation Under Regulation 31A Of SEBI Listing RegulationsMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2025
May 15, 2025Board Meeting Intimation for Intimation On Board MeetingMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Strides Acquires Identified Andas From Nostrum Laboratories Inc. USAApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 11, 2025
Apr 11, 2025Intimation For Change In Details Of Key Managerial Personnel For Determining Materiality Of Events Or Information And Making Disclosure To Stock Exchange Under Regulation 30 Of SEBI Listing RegulationsApr 03, 2025
Apr 03, 2025Update On Redemption Of Secured Unlisted Redeemable Non-Convertible DebenturesApr 01, 2025
Apr 01, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 21, 2025
Mar 21, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 21, 2025
Mar 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 19, 2025
Mar 19, 2025Proposed De-Merger Of Identified Business Of Arco Lab Private Limited (Arco Lab) A Wholly Owned Subsidiary Of The CompanyMar 19, 2025
Mar 19, 2025DissolutionMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 14, 2025
Mar 14, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 18, 2025
Feb 18, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Jan 30, 2025Integrated Filing (Financial)Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Board Meeting Outcome for Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31 2024Jan 30, 2025
Jan 30, 2025Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31 2024Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Jan 24, 2025Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing RegulationsJan 24, 2025
Jan 24, 2025Onesource Specialty Pharma Limited (Onesource) - IndiaS First Specialty Pharma CDMO Receives Listing And Trading Approval For Its Equity Shares From BSE And NSE.
Onesource To Start Trading In NSE Jan 23, 2025
Jan 23, 2025Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Globals Corporate Sustainability Assessment (CSA) 2024Jan 22, 2025
Jan 22, 2025Intimation About Receipt Of Order On Jan 20 2024 From The Transfer Pricing Officer Being Issued Under Section 92 CA (3) Of Income Tax Act 1961 For AY 22-23Jan 21, 2025
Jan 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 20, 2025
Jan 20, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 27, 2024
Dec 27, 2024Announcement under Regulation 30 (LODR)-Scheme of ArrangementDec 11, 2024
Dec 11, 2024Announcement under Regulation 30 (LODR)-Scheme of ArrangementDec 11, 2024
Dec 11, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 04, 2024
Dec 04, 2024Technical Indicators
RSI(14)
Neutral 65.94
ATR(14)
Less Volatile 33.94
STOCH(9,6)
Neutral 76.47
STOCH RSI(14)
Neutral 59.18
MACD(12,26)
Bullish 5.93
ADX(14)
Strong Trend 33.36
UO(9)
Bearish 54.39
ROC(12)
Uptrend And Accelerating 12.47
WillR(14)
Neutral -31.02
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 JM Small Cap Fund Direct - Growth | 0 | 0.00% | -1.22% | -1.70% | May 2025 | |
 Quant Business Cycle Fund Direct-Growth | 0 | 0.00% | -1.10% | -1.16% | May 2025 | |
| Quant Active Fund Direct-Growth | 0 | 0.00% | -0.97% | -1.01% | May 2025 | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 0 | 0.00% | -0.88% | -1.09% | May 2025 | |
| Quant Small Cap Fund Direct Plan-Growth | 0 | 0.00% | -0.83% | -0.90% | May 2025 | |
 ITI Pharma and Healthcare Fund Direct - Growth | 0 | 0.00% | -0.82% | -0.86% | May 2025 | |
 Aditya Birla Sun Life Pure Value Direct Fund-Growth | 0 | 0.00% | -0.67% | -0.69% | May 2025 | |
 Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth | 0 | 0.00% | -0.65% | -0.68% | May 2025 | |
 Bandhan Small Cap Fund Direct-Growth | 0 | 0.00% | -0.60% | -0.58% | May 2025 | |
| WhiteOak Capital Special Opportunities Fund Direct - Growth | 0 | 0.00% | -0.54% | -0.81% | May 2025 | |
| Bandhan BSE Healthcare Index Fund Direct-Growth | 0 | 0.00% | -0.35% | -0.36% | May 2025 | |
 Axis Flexi Cap Fund Direct-Growth | 0 | 0.00% | -0.20% | -0.21% | May 2025 | |
| Axis Small Cap Fund Direct-Growth | 0 | 0.00% | -0.20% | -0.22% | May 2025 | |
| Bandhan Midcap Fund Direct-Growth | 0 | 0.00% | -0.19% | -0.21% | May 2025 | |
 Groww Nifty Total Market Index Fund Direct - Growth | 0 | 0.00% | -0.02% | -0.02% | May 2025 | |
 Angel One Nifty Total Market Index Fund Direct - Growth | 0 | 0.00% | -0.02% | -0.02% | May 2025 | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0 | 0.00% | -0.02% | -0.02% | May 2025 | |
| Bandhan Nifty Total Market Index Fund Direct-Growth | 0 | 0.00% | -0.02% | -0.02% | May 2025 | |
| Aditya Birla Sun Life Retirement Fund - The 40s Plan Direct-Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 | |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 | |
| Aditya Birla Sun Life Flexi Cap Fund Direct-Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 | |
| JM ELSS Tax Saver Fund Direct Plan-Growth | 0 | 0.00% | 0.00% | -1.40% | May 2025 | |
| JM Flexicap Fund Direct Plan-Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 | |
| JM Midcap Fund Direct - Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 | |
| Aditya Birla Sun Life Retirement Fund - The 50s Plan Direct-Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
